Facts & Figures
Research Funding Information
Fiscal Year 2015, Psychiatry
Federal
Psychiatry - $9,057,968.00
Glahn, David PhD
Gene Networks Influencing Psychotic Dysconnectivity in African Americans. Yale University.
$1,771,191.00
Choi, Jimmy PhD
Intrinsic Motivation and Learning in Schizophrenia. NIH.
$150,363.00
Pearlson, Godfrey M.D.
“Functional Neuroimaging of Alcoholism Vulnerability: Glutamate, Reward, Impulsivity, and Payloyian-to-Instrumental Transfer (PIT), Part II – Saracatinib” Yale University.
$82,747.00
2 R01 MH077945-05A1 entitled 3/5 Bipolar-Schizophrenia Network for Intermediate Phenotypes 2. Yale University.
$3,027,500.00
Pearlson, Godfrey, M.D./ Stevens, Michael PhD
Neuroscience of Marijuana Impaired Driving. Yale University.
$1,204,945.00
Stevens, Michael PhD
Neural Architecture of Emotion Regulation, Adolescent Development and Depression. NIH.
$2,821,222.00
Foundation
Psychiatry - $22,070.97
Choi, Jimmy PhD
Neural Basis of Intrinsic Motivation in Schizophrenia. NARSAD.
$22,070.97
Industry
Psychiatry - $2,583,308.50
Malik, Salma M.D.
A Multicenter, Double-blind, Placebo- and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric patients With Major Depressive Disorder (VLZ-MD-22). Forest Research Institute.
$82,500.00
An Open-label Long-term Safety Study of Vilazodone in Pediatric Patients with Major Depressive Disorder. Forest Laboratories.
$132,800.00
Tolin, David PhD
Field Testing of an Online Diagnostic Checklist for Children, Adolescents, and Young Adults. Mindyra, LLC.
$2,888.00
Winokur, Andrew M.D./John Goethe, M.D.
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-4 Study) ALK5461-205. Premier Research.
$207,731.00
A Phase 3 Multicenter Study of the Long-term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepressant Therapy (the FORWARD-2 Study) (ALKS5461-208). INC Research, LLC.
$199,250.00
A Prospective, Longitudinal, Observational Study to Evaluate Potential Predictors of Relapse in Subjects with Major Depressive Disorder Who Have Responded to Antidepressant Treatment (OBSERVEMDD0001). Janssen Research & Development, LLC.
$388,229.00
An 8-week, randomized, phase 2, double-blind, Sequential parallel-group comparison study of Two dose levels of pf-06372865 compared to Placebo as an adjunctive treatment in Outpatients with inadequate response to Standard of care for generalized anxiety Disorder (Protocol # B7431007). InVentiv Clinical, LLC.
$119,781.00
A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects with Social Anxiety Disorder. Janssen Research & Development, LLC.
$98,559.50
A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression. Janssen Research & Development, LLC.
$1,351,570.00
Open Competition
Psychiatry - $21,753.00
Diefenbach, Gretchen PhD
Treating Anxiety with Cognitive Bias Modification Combined with Transcranial Magnetic Stimulation. HH-Endowment Funds. (OC)-129513.
$9,990.00
Hallion, Lauren, PhD
Cognitive Control as a Mechanism and Intervention Target in Emotional Disorders. HH-Endowment Funds (OC)-129513.
$1,800.00
Ng, Janet PhD
A mindfulness-based weight loss maintenance intervention to enhance bariatric surgery outcomes. HH-Endowment Funds (OC)-129513.
$9,963.00
Unfunded
Psychia - $0.00
Barrett, Jennifer B.A.
Olin Neuropsychiatry Research Center Volunteer Research Registry.
Registry $0.00
Emadi, Nazli, MD, PhD
Prediction of cognitive decline by 3MS and MoCA compared to brain volumetric MRI in Alzheimer’s disease.
$0.00
Pearlson, Godfrey, M.D.
“Functional Neuroimaging of Alcoholism Vulnerability: Glutamate, Reward, Impulsivity, and Payloyian-to-Instrumental Transfer (PIT), Part II – Saracatinib”.
$0.00
Bi-directional data sharing of neuroimaging data with the Human Connectome Project.
Peck, Caleb Psy.D.
Can the MMPI-2RF differentiate malingering from conversion disorders in a known samples study?
$0.00.
Tolin, David PhD
Development and Validation of the Broad Assessment Questionnaire.
$0.00
Young, Kevin PhD
Using psychological testing to enhance prediction of lethal suicide attempts.
$0.00
Comparing Autism Spectrum Disorders and Psychosis using the Rorschach: A Feasibility Study.
$0.00